A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination with Folate Receptor Alpha peptides with GM-CSF in patients with Triple Negative Breast Cancer

ID Number 16-1218

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


The ultimate intent of the vaccine is to prevent disease from recurring.  The vaccine is made from protein pieces that are found on ovarian and breast cancers.  To enhance the vaccine, the protein pieces are mixed with what is called an adjuvant, which alerts the immune system.  For this study, the adjuvant will be mixed with the vaccine prior to administration.  Another drug to be administered in the course of vaccination is cyclophosphamide.  It will be used at low dose, not to directly affect the cancer but to help enhance immunity.

Contact Information
Joni Gomes
(212) 824-7309

Recruiting Patients: Yes